EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn’s Disease in Italy

Melania Dovizio, Susanne Hartz, Carlotta Buzzoni, Isabel Redondo, Marijana Nedeljkovic Protic, Domenico Birra, Valentina Perrone, Chiara Veronesi, Luca Degli Esposti iD, Alessandro Armuzzi

Advances in Therapy · 2024

DOI: 10.1007/s12325-024-02840-x ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Advances in Therapy, 2024. Verfasst von Melania Dovizio und 9 weiteren Autor:innen. Beteiligte Einrichtung: CliCon S.R.L. Società Benefit Health, Economics and Outcomes Research, Via Murri, 9-40137, Bologna, Italy. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Real-world data are used to inform decision-makers and optimise therapeutic management for patients with ulcerative colitis (UC) and Crohn's disease (CD). We analysed data on the epidemiology (by using proxies of prevalence and incidence), patient characteristics, treatment patterns and associated healthcare direct costs for the management of patients with UC and patients with CD in Italy. METHODS: This retrospective observational study used administrative databases from eight Local Health Units geographically distributed across Italy. Adult patients with a hospitalisation and/or an exemption for UC or CD were included. Study outcomes were summarised descriptively, and limited statistical tests were performed. RESULTS: At baseline, 9255 adults with UC and 4747 adults with CD were included. Mean (standard deviation) age at inclusion was 54.0 (18.4)/48.6 (18.1) years, for UC/CD. The estimated average incidence of UC and CD for the period 2013-2020 was 36.5 and 18.7 per 100,000, respectively. The most frequently prescribed drug category for patients with UC/CD was conventional treatment [mesalazine and topical corticosteroids (67.4%/61.1%), immunomodulators and systemic corticosteroids (43.2%/47.7%)], followed by biologic treatments (2.1%/5.1%). The mean annual total direct cost per patient was 7678 euro (€), for UC and €6925 for CD. CONCLUSION: This analysis, carried-out in an Italian clinical setting, may help to optimise therapy for patients with UC and CD and provide relevant clinical practice data to inform decision-makers. Data from clinical practice can be used to guide healthcare decisions and optimise treatment for patients with ulcerative colitis and Crohn’s disease. This study used anonymised patient information from almost four million individuals across Italy to describe the epidemiology, patient characteristics, treatment patterns and healthcare costs of patients with ulcerative colitis and Crohn’s disease. Adults with an Italian National Health System code in their records associated with the diagnosis of ulcerative colitis or Crohn’s disease were included. Baseline characteristics were balanced between groups and rates of perceived incidence were numerically similar to the results reported in similar Italian studies. This study found that patients with ulcerative colitis and Crohn’s disease were most often prescribed conventional treatments, and biological treatments were least-commonly prescribed. More than half of patients with ulcerative colitis and nearly half of those with Crohn’s disease were persistent with first (index) treatment of mesalazine and topical corticosteroids and with biologic index treatment during the follow-up period. Switch occurred in up to approximately a quarter of patients with ulcerative colitis and Crohn’s disease. The main factors that predicted switch were index biologic for ulcerative colitis and baseline comorbidities for Crohn’s disease. The average direct cost per patient in 1 year was 7678 euro (€) for ulcerative colitis and €6925 for Crohn’s disease. The results of this analysis may help to optimise therapy for patients with ulcerative colitis and Crohn’s disease, and to inform decision-makers in healthcare systems on which treatment options provide value for money and benefit patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCrohn DiseaseHumansItalyMaleFemaleRetrospective StudiesMiddle AgedAdultAgedIncidenceHealth ResourcesHealth Care Costs

Stichwörter der Autor:innen

Healthcare costInflammatory bowel diseaseReal-world evidenceTherapeutics

Autor:innen und Institutionen

  • CliCon S.R.L. Società Benefit Health, Economics and Outcomes Research, Via Murri, 9-40137, Bologna, Italy.
  • Eli Lilly and Company, Indianapolis, IN, USA.
  • Eli Lilly and Company, Indianapolis, IN, USA. luca.degliesposti@clicon.it.
  • IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

ORCID-Profile: Luca Degli Esposti

Förderung

  • Eli Lilly and Company

Zitieren

APA

Dovizio, M., Hartz, S., Buzzoni, C., Redondo, I., Nedeljkovic Protic, M., Birra, D., Perrone, V., Veronesi, C., Degli Esposti, L., & Armuzzi, A. (2024). Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn’s Disease in Italy. Advances in Therapy. https://doi.org/10.1007/s12325-024-02840-x

Vancouver

Dovizio M, Hartz S, Buzzoni C, Redondo I, Nedeljkovic Protic M, Birra D, et al. Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn’s Disease in Italy. Advances in Therapy. 2024. doi:10.1007/s12325-024-02840-x

BibTeX
@article{Dovizio2024,
  author = {Dovizio, Melania and Hartz, Susanne and Buzzoni, Carlotta and Redondo, Isabel and Nedeljkovic Protic, Marijana and Birra, Domenico and Perrone, Valentina and Veronesi, Chiara and Degli Esposti, Luca and Armuzzi, Alessandro},
  title = {Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn’s Disease in Italy},
  journal = {Advances in Therapy},
  year = {2024},
  doi = {10.1007/s12325-024-02840-x}
}
Kostenlos starten →